Preparing a CIM and data room that buyers can actually use

Tell a coherent business story, make the numbers traceable and control confidential information.

Educational owner resource. Read the cited sources and obtain advice for your circumstances.

Explain the business before collecting every file

A confidential information memorandum, or CIM, gives a potential buyer an organized description of the opportunity. It should explain what the pharmacy does, how earnings are produced, what the owner contributes and which risks need investigation. A convincing document connects statements to evidence rather than using adjectives such as exceptional or turnkey.

Start with a business overview, service mix, three-year financial summary, normalization bridge, staffing model, premises and lease, material agreements, risks and a proposed transition. Keep dates and periods consistent. Separate historical facts, management explanations and future possibilities so readers can tell what has actually happened.

Give every important number a route back to evidence

Tie the annual summary to financial statements and the normalization schedule to ledger detail. Explain differences between accounting revenue, dispensing-system totals and cash receipts rather than forcing them to match. Specify whether professional services, front-shop sales and drug product revenue are classified consistently. If a measure changes definition, disclose the change.

The mock CIM in this hub is entirely fictional and demonstrates the format, not a comparable sale. It uses internally consistent financials and both positive and negative adjustments. In a real document, unconfirmed adjustments should remain visibly unconfirmed. Potential growth projects belong in an opportunity section with costs and dependencies; they should not inflate historical earnings.

Create a controlled index rather than a document dump

Organize folders by topic: corporate, financial, operations, premises, people, contracts, regulatory and transaction. Assign each file a date, owner and version. Maintain a questions log showing the request, responsible person, response and supporting file. A missing document should have an explicit status and expected resolution date. This prevents multiple advisors from circulating different versions of the same answer.

Grant access in stages and to named recipients. Start with aggregated, appropriately redacted material. Do not use the public resource-centre forms to send patient information, prescriptions, staff identification records or credentials. An NDA is useful but does not establish that every disclosure is lawful.

Make privacy and gaps part of preparation

PIPEDA’s business-transaction provisions are conditional; they address necessary information, appropriate agreements, safeguards and other requirements. Applicable provincial and health-information rules also need qualified review. Department of Justice Canada Decide with your advisors what can be disclosed, to whom, at which stage and under which controls before uploading sensitive files.

A useful CIM acknowledges concerns early. State a lease renewal date, vacant role, disputed earnings adjustment or contract dependency plainly, then explain the available evidence and proposed remedy. Buyers can investigate a clear issue more efficiently than an unexplained contradiction. Use our document checklist to build an index and our fictional CIM to see the intended structure. A confidential review can identify the few gaps to fix before a broader process begins.

Continue reading

Pharmacy financial figures: gross profit, gross margin, NOI and EBITDA

Pharmacy share or asset purchase agreement: what sellers should expect

Selling a pharmacy in Canada: what happens from an accepted offer to closing?

Sources and context

PIPEDA, section 7.2: business transactions
Conditional federal business-transaction provisions. Applicability and provincial health-information requirements must be reviewed; an NDA alone does not satisfy every condition. Accessed 2026-10-14.

How to conduct due diligence when buying a business
Generic acquisition diligence guidance; not pharmacy-specific obligations or legal wording.

Browse all articles and exit guides →

Plan your next conversation

Smith & Bederman Advisory Group supports independent Canadian pharmacy owners with sales, acquisitions, valuation and succession planning.

Explore valuation and EBITDA tools · Check exit readiness · Book a confidential consultation

Calculator access, full buyer profiles and downloads are available through the Resource Centre’s access form.